drugset / Trial / NCT01262872

Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants

NCT01262872

RandomizedParallel-groupDouble-blindPrevention

Summary

This study will assess the impact on nasopharyngeal carriage, safety and immunogenicity of GSK Biologicals' pneumococcal vaccine 2189242A given as a 3-dose vaccination course and co-administered with other routine paediatric vaccines in infants in The Gambia. Two formulations containing different doses of pneumococcal antigen and two different schedules will be tested in infants.

Timeline

Start
2011-02-09
Primary completion
2013-03-18
Completion
2013-03-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK2189242A Vaccine Intramuscular
Subject M-Vac™ Vaccine Intramuscular
Subject Polio Sabin Vaccine Oral
Comparator Prevnar 13 Vaccine Intramuscular
Comparator Synflorix Vaccine Intramuscular
Subject Tritanrix™-HepB/Hib Unknown Intramuscular
Subject Yellow Fever Vaccine Vaccine Intramuscular